• Commit®
• Nicorette®

Commit^®

Geared to help smokers quit

• In a large clinical trial (>1,800 subjects), 49% of the Commit 4 mg users remained smoke free at 6 weeks vs 21% for placebo ( P<0.001)⁶
• 46% of 2 mg Commit users were smoke free at 6 weeks vs 30% for placebo ( P<0.001)⁶
• Abstinence rate achieved with 4 brief behavioral intervention contacts (5 to 10 minutes)⁶

• Highly dependent smokers⁹*
• Smokers previously unsuccessful on prior pharmacological treatment¹⁰ 4 mg Commit reduces weight gain associated with quitting
• 4 mg Commit users experienced less weight gain compared with placebo: 2.3 lb less at 6 weeks; 1.6 lb less at 12 weeks; weight gain was equal at 6 months⁶

Established Heritage

• Over 5 million smokers worldwide have quit smoking with the help of Commit and other NRT products from GlaxoSmithKline²

Commit: proven smoking cessation with low level of behavioral intervention

Intensive interventions in clinical trials may not mirror real-world practice³

Sources:

1. Chantix [Product Information]. New York, NY: Pfizer Inc; 2006.

2. Data on file. GlaxoSmithKline.

3. Solberg LI, Asche SE, Boyle RG, Boucher JL, Pronk NP. Frequency of physician-directed assistance for smoking cessation in patients receiving cessation medications. Arch Intern Med. 2005;165:656-660.

4. Shiffman S, Dresler CM, Hajek P, Gilburt SJA, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162:1267-1276.

5. Jorenby DE, Hays JT, Rigotti NA, et al, for the Varenicline Phase 3 Study Group. Efficacy of varenicline, an 2 4 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.

6. Gonzales D, Rennard SI, Nides M, et al, for the Varenicline Phase 3 Study Group. Varenicline, an 2 4 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.

Proven efficacy

4 mg Commit doubles quit rates with low level of behavioral intervention¹

Smoke-free 4 mg Commit users¹

• 49% at 6 weeks (vs 21% for placebo; OR [odds ratio] 3.69)
• 35% at 12 weeks (vs 14% for placebo; OR 3.42)
• 15% at 52 weeks (vs 6% for placebo; OR 2.69)

Compliance improves efficacy¹

• Quit rates were 57% (30% placebo) at 6 weeks for those smokers in the 4 mg lozenge group who used more than 9 lozenges per day in the first 2 weeks¹
• The minimum dosage in the first 6 weeks is 9 lozenges per day

Recommend first line

Proven efficacy even for the more challenging smokers

• Heavily addicted smokers³: FTND* >7
• Smokers with a history of unsuccessful quit attempts including those using pharmacological treatment⁴
  • — In a study of 1,818 smokers, over 80% of participants had made at least one previous quit attempt and 63% had previously tried using a pharmacologic agent

Reduces weight gain associated with quitting

• 2.3 lb less at 6 weeks
• 1.6 lb less at 12 weeks
• Weight gain in the placebo and treatment groups was equal at 6 months

Excellent Safety

• Commit can be used safely even in patients with cardiac disease, diabetes, and hypertension⁵

Sources:

1. Shiffman S, Dresler CM, Hajek P, Gilburt SJA, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162:1267-1276.

2. Data on file. GlaxoSmithKline

3. Shiffman S, Di Marino ME, Pillitteri JL. The effectiveness of nicotine patch and nicotine lozenge in very heavy smokers. J Subst Abuse Treat. 2005;28:49-55.

4. Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction. 2004;99:83-92.

5. Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs KR. Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study. Clin Ther. 2005;27:1571-1587.

^ Back to top

Nicorette^®

• Use of Nicorette resulted in significantly greater reductions in craving (F1,285=13.81, P<0.001) than control¹
  
  
• Craving dropped significantly faster among subjects using active gum (F1,158=10.65, P=0.001) compared to control¹
  
  
• In minutes 10-15, subjects using active gum showed significantly steeper drops in craving (F1,158=7.35, P=0.008); by 15 minutes, and at every time point thereafter, participants on active gum demonstrated significantly lower craving than those on control¹
  
  

^ Back to top

Sources:

1. Durcan MJ, De’Ath J, Targett D, Marsh H, Chan R, Ong TJ (2003) Efficacy of the nicotine lozenge in relieving cue provoked cravings. Poster presented at the annual European meeting of the Society for Research on Nicotine and Tobacco, Padua, Italy.

< Back